Ultragenyx Pharmaceutical ( NASDAQ: RARE ) announces the pricing of its underwritten public offering of 7,435,898 shares of its common stock at $39.00 per share, and pre-funded warrants offering to purchase 1,538,501 shares of its common stock at a purchase price of $38.999 per pre-funded warrant, for expected gross proceeds of $350 million.
In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,346,153 shares of the company's common stock at the public offering price. The offering is expected to close on or about June 17, 2024. More on Ultragenyx Pharmaceutical Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching Ultragenyx to file for accelerated approval of rare metabolic disease candidate Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy Seeking Alpha’s Quant Rating on Ultragenyx Pharmaceutical.
